Home » Topics » BioWorld Science

BioWorld Science
RSS

Teva discontinues development of fremanezumab for cluster headaches

April 24, 2019

Innovent begins phase I trial of PD-1/PD-L1 bispecific antibody IBI-318

April 24, 2019

Takeda communicates data on ART-648 in preclinical models of NASH

April 24, 2019

Preclinical characterization detailed for phase I cancer candidate S-64315/MIK-665

April 24, 2019

Fujifilm presents new antibacterials

April 24, 2019

Beijing Yuezhikangtai Biomedicines identifies hedgehog-signaling inhibitors

April 24, 2019

MET-409 is safe and well tolerated in phase I study in healthy male subjects

April 24, 2019

Phase I data reported for RO-7049389 in patients with chronic HBV infection

April 24, 2019

MGL inhibitors revealed in Takeda Pharmaceutical patent

April 24, 2019

Preclinical characterization of humanized anti-MERTK monoclonal antibody, RGX-019

April 24, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...